Correction to: In Vivo Delivery of Nucleic Acid-Encoded Monoclonal Antibodies.
- Published in:
- 2020
- By:
- Publication type:
- Correction Notice
Works matching IS 11738804 AND DT 2020 AND VI 34 AND IP 3
Results: 12
1
2
Correction to: Effectiveness of Switching from Reference Product Infliximab to Infliximab-Dyyb in Patients with Inflammatory Bowel Disease in an Integrated Healthcare System in the United States: A Retrospective, Propensity Score-Matched, Non-Inferiority Cohort Study
- Published in:
- 2020
- By:
- Publication type:
- Correction Notice
3
The Path Towards a Tailored Clinical Biosimilar Development.
- Published in:
- BioDrugs, 2020, v. 34, n. 3, p. 297, doi. 10.1007/s40259-020-00422-1
- By:
- Publication type:
- Article
4
The Role of Immune Checkpoint Inhibitors in Colorectal Adenocarcinoma.
- Published in:
- BioDrugs, 2020, v. 34, n. 3, p. 349, doi. 10.1007/s40259-020-00420-3
- By:
- Publication type:
- Article
5
Cell-Free Protein Synthesis: A Promising Option for Future Drug Development.
- Published in:
- BioDrugs, 2020, v. 34, n. 3, p. 327, doi. 10.1007/s40259-020-00417-y
- By:
- Publication type:
- Article
6
Ongoing Developments and Clinical Progress in Drug-Loaded Red Blood Cell Technologies.
- Published in:
- BioDrugs, 2020, v. 34, n. 3, p. 265, doi. 10.1007/s40259-020-00415-0
- By:
- Publication type:
- Article
7
Haematopoietic Stem Cell Transplantation for Multiple Sclerosis: Current Status.
- Published in:
- BioDrugs, 2020, v. 34, n. 3, p. 307, doi. 10.1007/s40259-020-00414-1
- By:
- Publication type:
- Article
8
In Vivo Delivery of Nucleic Acid-Encoded Monoclonal Antibodies.
- Published in:
- BioDrugs, 2020, v. 34, n. 3, p. 273, doi. 10.1007/s40259-020-00412-3
- By:
- Publication type:
- Article
9
Biosimilar Pegfilgrastim: Improving Access and Optimising Practice to Supportive Care that Enables Cure.
- Published in:
- BioDrugs, 2020, v. 34, n. 3, p. 255, doi. 10.1007/s40259-020-00411-4
- By:
- Publication type:
- Article
10
Effectiveness of Switching from Reference Product Infliximab to Infliximab-Dyyb in Patients with Inflammatory Bowel Disease in an Integrated Healthcare System in the United States: A Retrospective, Propensity Score-Matched, Non-Inferiority Cohort Study.
- Published in:
- BioDrugs, 2020, v. 34, n. 3, p. 395, doi. 10.1007/s40259-020-00409-y
- By:
- Publication type:
- Article
11
Comparison of the Efficacy and Safety of Adalimumab (Humira) and the Adalimumab Biosimilar Candidate (HS016) in Chinese Patients with Active Ankylosing Spondylitis: A Multicenter, Randomized, Double-Blind, Parallel, Phase III Clinical Trial.
- Published in:
- BioDrugs, 2020, v. 34, n. 3, p. 381, doi. 10.1007/s40259-020-00408-z
- By:
- Publication type:
- Article
12
Demonstrating Analytical Similarity of Trastuzumab Biosimilar HLX02 to Herceptin® with a Panel of Sensitive and Orthogonal Methods Including a Novel FcγRIIIa Affinity Chromatography Technology.
- Published in:
- BioDrugs, 2020, v. 34, n. 3, p. 363, doi. 10.1007/s40259-020-00407-0
- By:
- Publication type:
- Article